LDS/Medical Tests/Dopamine D1 receptor (DRD1) Antibody, IgG

Dopamine D1 receptor (DRD1) Antibody, IgG

The Dopamine D1 receptor (DRD1) Antibody, IgG assay measures the antibody titer against the neuronal antigen Dopamine D1 and compares this measurement to a normal control titer against Dopamine D1. Production of human monoclonal antibodies (mAbs) from patients with elevated anti-neuronal autoantibodies against the D1 receptor shows that these anti-D1R antibodies bind to the receptor or change its structure allosterically to cause a 50-fold increase in response to dopamine by the dopamine receptor. Two types of anti-neuronal human antibodies against the dopamine receptors were found to induce increased dopamine release and also alter the receptors to cause an increase in their activity and sensitivity to dopamine. Thus, these antibodies are likely important in pathogenesis of neuropsychiatric diseases.

The Dopamine 1 (DRD1) Antibody, IgG is one of the five tests which comprise The Cunningham Panel™ of Tests. The Cunningham Panel™ tests measure human serum Immunoglobulin G (IgG) levels by Enzyme-Linked ImmunoSorbent Assay (ELISA) directed against: Dopamine D1 Receptor (DRD1), Dopamine D2L Receptor (DRD2L), Lysoganglioside-GM1 (LYSO-GM1) and Tubulin (TUB). ELISA results are determined by measuring the colorimetric intensity at a specific wavelength which is directly proportional to the amount of antibody in the sample. The fifth assay of this panel measures the specific activity of calcium/calmodulin-dependent protein kinase II (CaM KII) induced by the patient’s serum in cultured human neuronal cell lines compared to controls. This panel measures the level of these antibodies, and the ability of the patient’s sera to stimulate CaM KII at a single point in time.

The Cunningham Panel™ of Tests is a proprietary test panel exclusively offered by Moleculera Labs. For more information please see www.moleculeralabs.com.

  • As an aid in diagnosis and management of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus (PANDAS)
  •  As an aid in diagnosis and management of pediatric acute-onset neuropsychiatric syndrome (PANS)
  •  As an aid in diagnosis and management of Sydenham's chorea (post Rheumatic Fever)
  •  As an aid in diagnosis and management of Autism spectrum disorder, specifically regressive autism, that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of treatment resistant psychiatric illnesses and symptoms that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of chronic depression that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of anxiety disorders that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of  ADHD/ADD that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of OCD that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of Tourette’s Syndrome that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of bipolar depression that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of new onset enuresis/incontinence that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of rage disorder that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of ODD that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of behavioral regression that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of cognitive decline that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of sensory abnormalities that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of dysgraphia that could have an anti-neuronal autoimmune basis
  •  As an aid in diagnosis and management of anorexia that could have an anti-neuronal autoimmune basis

If any one (1) or more of these five (5) assay values is elevated, it may indicate a clinically significant autoimmune neurological condition.

Note: It is important to note that the degree of elevation in assay values may not necessarily correlate with degree of symptom severity. Any value above normal ranges may correlate with symptomatology. Results may vary depending on the patient’s condition and status, whether they are on immunosuppressive agents, corticosteroids or other immune modulatory therapy, and the length of time post treatment.

Reference ranges based on pediatric control group:

 

  Anti-Dopamine Receptor D1 (titer) Anti-Dopamine Receptor D2L (titer) Anti-Lysoganglioside GM1 (titer) Anti-Tubulin (titer) CaM Kinase II (% of baseline)
Normal Ranges 500 - 2,000 2,000 - 8,000 80 - 320 250 - 1,000 53 - 130
Normal Mean 1,056 6,000 147 609 95

 

Enzyme-Linked Immunosorbent Assays (ELISAs).

Serum (Red top tube).

4-5 mL serum collected in red-top glass tube with no additives or gel barrier. Ship on two fully frozen 8-ounce ice packs, overnight only Monday-Thursday. Do not ship on Friday or before a US holiday.

Stability

  • Frozen: 1 year
IgG and IgM titer measurement for any known or suspected past, recent, or current infection, testing for general metabolic and genetic markers such as GAD 65, MTHFR; testing for IgG and/or IgM to EBV, CMV, HHV6 and other viruses in the Herpes family, Lyme Disease IgG, IgM; Babesisia and Bartonella antibodies, ASO titer, DNaseB titers, Group A strep blood cultures.
Approximately 2 -3 weeks
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login